Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

I Sæterdal, J Bjørheim, K Lislerud… - Proceedings of the …, 2001 - National Acad Sciences
I Sæterdal, J Bjørheim, K Lislerud, MK Gjertsen, IK Bukholm, OC Olsen, JM Nesland…
Proceedings of the National Academy of Sciences, 2001National Acad Sciences
The functional role and specificity of tumor infiltrating lymphocytes (TIL) is generally not well
characterized. Prominent lymphocyte infiltration is the hallmark of the most common form of
hereditary colon cancer, hereditary nonpolyposis colon cancer (HNPCC) and the
corresponding spontaneous colon cancers with the microsatellite instability (MSI)
phenotype. These cancers are caused by inherited or acquired defects in the DNA mismatch–
repair machinery. The molecular mechanism behind the MSI phenotype provides a clue to …
The functional role and specificity of tumor infiltrating lymphocytes (TIL) is generally not well characterized. Prominent lymphocyte infiltration is the hallmark of the most common form of hereditary colon cancer, hereditary nonpolyposis colon cancer (HNPCC) and the corresponding spontaneous colon cancers with the microsatellite instability (MSI) phenotype. These cancers are caused by inherited or acquired defects in the DNA mismatch–repair machinery. The molecular mechanism behind the MSI phenotype provides a clue to understanding the lymphocyte reaction by allowing reliable prediction of potential T cell epitopes created by frameshift mutations in candidate genes carrying nucleotide repeat sequences, such as TGFβRII and BAX. These tumors therefore represent an interesting human system for studying TIL and characterizing tumor-specific T cells. We here describe T cell reactivity against several T helper cell epitopes, representing a common frameshift mutation in TGFβRII, in TIL and peripheral blood lymphocytes from patients with MSI+ tumors. The peptide SLVRLSSCVPVALMSAMTTSSSQ was recognized by T cells from two of three patients with spontaneous MSI+ colon cancers and from all three patients with HNPCC. Because such mutations are present in 90% of cancers within this patient group, these newly characterized epitopes provide attractive targets for cancer vaccines, including a prophylactic vaccine for individuals carrying a genetic disposition for developing HNPCC.
National Acad Sciences